4//SEC Filing
Greenhalgh Ellis Skott 4
Accession 0001192482-19-000422
CIK 0001561921other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 8:49 PM ET
Size
15.7 KB
Accession
0001192482-19-000422
Insider Transaction Report
Form 4
TELA Bio, Inc.TELA
Greenhalgh Ellis Skott
Chief Science Officer
Transactions
- Conversion
Common Stock
2019-11-13+2,025→ 5,623 total - Conversion
Common Stock
2019-11-13+4,887→ 10,510 total - Conversion
Series A Preferred Stock
2019-11-13−50,000→ 0 total→ Common Stock (2,025 underlying) - Conversion
Series B Preferred Stock
2019-11-13−120,699→ 0 total→ Common Stock (4,887 underlying) - Conversion
Warrant (right to buy)
2019-11-13+1,976→ 1,976 totalExercise: $28.65From: 2019-11-13Exp: 2027-01-18→ Common Stock (80 underlying) - Conversion
Warrant (right to buy)
2019-11-13−1,976→ 0 totalExercise: $1.16From: 2017-01-18Exp: 2027-01-18→ Series B Preferred Stock (1,976 underlying)
Footnotes (5)
- [F1]Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]Reflects 5,623 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
- [F3]Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F4]Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
- [F5]Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.
Documents
Issuer
TELA Bio, Inc.
CIK 0001561921
Entity typeother
Related Parties
1- filerCIK 0001790671
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 8:49 PM ET
- Size
- 15.7 KB